PL-05 MIDAS Public Disease Model  by Cooley, P. et al.
S32 Plenary Sessions
Fig. 1.
N
HO
MeO
OMe
OMe
jatrorrhizine
N
O
O
OMe
OMe
beberine
N
MeO
MeO
OMe
OMe
palmatine
NH2N NH2
Proflavine
N
O
O
OMe
OMe
chelerythrine sanguinarine
N
O
O
O
O
Fig.2a.
Fig.2b.
Fig.2c.
PL-04 Communicable diseases surveillance lessons
learned from developed and developing
countries: literature review
N. Sahal1 *, R. Reintjes2, A.R. Aro1. 1Unit for Health
Promotion Research, Institute of Public Health,
University of Southern Denmark (SDU), Esbjerg, Denmark,
2Department of Public Health, Faculty of Life Sciences,
Hamburg University of Applied Sciences, Hamburg,
Germany
Background: Surveillance of infectious diseases is
recognized as the cornerstone of public health decision-
making and practice. The aim of the evaluation of
communicable diseases surveillance systems (CDSS) is
ensuring that communicable diseases are monitored
efﬁciently and effectively. The aim of this paper is to
reﬂect on the experiences of both developed and developing
countries in the evaluation of CDSS in order to learn lessons
from these experiences to improve systems everywhere.
Methods: A literature review of studies published in English
in PubMed and data bases of the World Health Organization
(WHO), and Center of Diseases Control (CDC) from 1981
to 2007 was undertaken assessing CDSS. The studies
were divided into those from developed and developing
countries.
Results: A total of 32 studies were included, 20
from developed and 12 from developing countries. Both
developed and developing countries faced difﬁculties in
CDSS. Studies from the developed countries have been
analyzed based on the quality of the system alone. In
developing countries, most of the studies have been on
the integrated diseases surveillance (IDSR) and have been
performed shortly after the adoption of the IDSR. Thus it
might be too early to make a fair evaluation. Some of the
systems over-centralized, while some lacked private health
sector involvement in the system. Further, some of the
systems were affected by conﬂicts and civil wars which are
common problems in developing countries.
Conclusion: None of the countries had ideal CDSS. The
strategy of integrated diseases surveillance seems to be
functioning well especially in Africa.
PL-05 MIDAS Public Disease Model
P. Cooley*, J. Cajka, B. Chasteen, L. Ganapathi,
W. Wheaton, D. Wagener. RTI International, Box 12194,
RTP, N.C., 27709, USA
The MIDAS∗ Public Disease Model is an agent based model
(ABM) that uses synthetic data to simulate and describe
inﬂuenza transmission within speciﬁc U.S. geographic areas.
Each person in the region of interest is an agent and each
agent is described by a number of demographic traits that
deﬁne the social network interactions that the agents are
part of. The agent traits that compromise the synthetic
data were developed from US census, National Education
Association and a provider of business information, InfoUSA,
data sources. They represent the U.S. population at the
time of the 2000 Census. The data include:
• A household in every Census tract that corresponds to a
household in the 2000 Census.
• Persons who live in those households within the tracts
such that their important Census tract level demographic
characteristics match those of the 2000 Census.
• Locations of all public and private schools as well as
pre-school and daycare facilities in the US that match a
variety of publicly available sources. Location, enrollment
and grade-level information are also deﬁned.
• An age-speciﬁc school assignment plan that deﬁnes the
schools attended by each school eligible person in the
population.
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• Group quarters at the community level that include the
location, size, and type of nursing home facilities and
mental health facilities.
• Major roads, state, metropolitan area, and county
boundaries.
• Bus routes in select communities.
This model advances the state of disease transition modeling
science by developing a set of documented tools that
constitute an analog to a higher level language that supports
the rapid development of large ABMs for studying problems
analogous to disease transmission problems. This resource
uses the above data resources deﬁnes above and it permits
the properties of ABMs, the natural history of infectious
diseases and the characteristics of the social networks
that those diseases utilize transmit within to be studied
experimentally.
*MIDAS Models of Infectious Disease Agents Study.
PL-06 Examining the fourth stage of epidemiological
transition in China: Some implications for health
and health care provision
M.M. Islam*, L.J. Pei, X.M. Song, X.Y. Zheng. Institute of
Population Research, Peking University, Beijing-100871,
China
Today’s China is experiencing the new epidemiological
phase, characterized by increasing life expectancy and
disease of afﬂuence coupled with emerging and re-emerging
diseases. Under this situation it is important to think
strategically in the planning of health care provision of
all population which is particularly important for rapidly
modernizing present China. The aim of this paper is to
analyze the fourth stage of epidemiological transition in
current China based on existing theoretical framework by
using descriptive statistical methods of analysis and to
seek for some policy implications for health and health
care provisions. Mortality data suggests that China has well
entered to the fourth stage of epidemiological transition-the
age of delayed degenerative diseases where Cardiovascular,
cancer, respiratory and digestive diseases are the leading
causes of death while the life expectancy has reached to
more than 70 years. Study indicates that the increase in
non-communicable diseases signiﬁcantly increases the cost
of illness and the burden of health care system. Moreover
HIV/AIDS, and other emerging diseases like bird ﬂu, SARS
have become new threats to public health. Demographic
and life style changes are likely to result in a substantial
increase in non-communicable diseases in next coming years
where it is an urgent priority to execute the policies to
prevent the growing epidemics. Thus this paper examines
the predominant major degenerative causes of death and
the risk of dying from these diseases redistributing to older
ages of people in China and to point out the new targets of
health care policies under changing dilemmas.
PL-07 HIV and TGF-b1 regulates HCV replication through
multiple pathways
W.Y. Lin*, E.M. Weinberg, R.X. Shao, L.F. Peng, R.T. Chung.
Gastrointestinal Unit, Massachusetts General Hospital,
Harvard Medical School, Boston, MA 02114, USA
Background: HIV co-infection increases HCV-related hepatic
ﬁbrosis progression, HCV persistence, and decreases
response rates to interferon-based anti-HCV therapy. We
have demonstrated that HIV increases HCV replication
through enhancement of TGF-b1 expression. We sought to
further explore the mechanism by which TGF-b1 regulates
HCV through TGF-b1 signal pathways.
Methods: Huh7.5.1 cells were incubated with active or heat
inactivated JFH1. Human TGF-b1 was tested for its effect on
JFH1 uptake and replication. HCV levels in cell lysates were
analyzed by HCV core ELISA and Q-PCR. TGF-b1 signaling
was measured using a highly TGF-b1 responsive PAI1-Luc
reporter construct. The effects of the ERK1/2 inhibitor
U0126 and the PI3K inhibitor Ly294002 on JFH1 replication
were analyzed.
Results: TGF-b1 increased active uptake of both active and
inactivated JFH1 by over 3 fold at 4 hrs, and increased
active JFH1 uptake and replication by over 5-fold at 24
hrs compared to untreated cells. U0126 decreased HCV
replication by 67% and blocked TGF-b1 mediated PAI1
promoter signaling by 2.2-fold in Huh7.5.1 cells and 3.6-
fold in JFH1-infected Huh7.5.1 cells. U0126 reduced TGF-
b1 stimulated phospho-ERK1/2 in both uninfected and
JFH1-infected Huh7.5.1 cells by Western blot. In contrast,
Ly294002 did not block TGF-b1 mediated PAI1 promoter
transcription or HCV replication enhancement.
Conclusions: Our data conﬁrm that HIV appears to promote
HCV replication through upregulating TGF-b1 in HCV-
infected hepatocytes. TGF-b1 has a permissive effect on
HCV uptake and replication. HCV replication enhancement
takes place through both indirect (increasing viral uptake)
and direct (regulation of HCV replication) means.
PL-08 Activation of VEGF-A/AKT/mTOR signal in
ground glass hepatocytes and transgenic livers
of Pre-S mutant: Implication for hepatitis B
virus-related hepatocarcinogenesis
J.C. Yang2 *, C.F. Teng2, H.C. Wu1, I.J. Su1,2. 1Division of
Clinical Research, National Health Research Institutes,
Tainan, Taiwan, 2Graduate Institutes of Basic Medicine
Sciences, National Cheng Kung University College of
Medicine, Tainan, Taiwan
Background and Aim: Ground glass hepatocytes (GGH)
harbor HBV pre-S mutants in endoplasmic reticulum (ER) and
represent the precursor lesions of hepatocellular carcinoma
(HCC). Whether growth factors play a role in the progression
from GGHs to HCC is investigated.
Methods: Growth factor(s) upregulated by pre-S mutants
was identiﬁed using a cytokine/growth factor array in
Huh-7 cells. Immunohistochemistry, RT-PCR, and Western
blot analysis were performed to study the participation of
these genes and their pathways in cells, liver tissues, and
transgenic livers.
Results: Vascular endothelial growth factor (VEGF)-A was
identiﬁed as the potential growth factor upregulated
by pre-S mutants. By immunohistochemistry, GGHs and
the transgenic mouse livers of pre-S2 mutant showed
enhanced expression of VEGF-A. The VEGF-A upregulation
by pre-S mutants could be suppressed by vomitoxin, an
ER stress inhibitor. Furthermore, pre-S mutants-expressed
Huh-7 cells exhibited activation of Akt/mTOR signaling
and increased growth advantage, which could be inhibited
by VEGF-A neutralization. Consistent with this notion,
enhanced expression of VEGF-A and activation of Akt/mTOR
signaling, comparable to the levels of paired HCC tissues,
were also detected in HBV-related non-tumorous livers.
Conclusion: The enhanced expression of VEGF-A in GGHs,
probably associated with pre-S mutants-induced ER stress,
may provide a potential mechanism for the progression from
GGHs to HCC through Akt/mTOR signaling in chronic HBV
infection.
